Published in Can J Gastroenterol on March 01, 2013
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology (2000) 3.49
HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol (2000) 2.60
The role of liver biopsy in chronic hepatitis C. Hepatology (2001) 2.47
Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology (2002) 2.37
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology (1998) 1.95
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut (2002) 1.65
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59
Hepatitis C: the clinical spectrum of the disease. J Hepatol (1999) 1.55
The natural history of recurrent hepatitis C and what influences this. Liver Transpl (2008) 1.38
Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl (2005) 1.27
Early hepatic stellate cell activation predicts severe hepatitis C recurrence after liver transplantation. Liver Transpl (2005) 1.22
Liver allograft pathology: approach to interpretation of needle biopsies with clinicopathological correlation. J Clin Pathol (2009) 1.18
Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation (2007) 1.08
One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl (2004) 1.07
What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol (2005) 1.06
Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology (2000) 1.02
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis (2009) 0.97
Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation (2007) 0.95
Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl (2005) 0.93
The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl (2008) 0.92
Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat (2001) 0.92
Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine (2004) 0.91
Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl (2006) 0.88
Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl (2011) 0.87
Platelet-derived growth factor gene polymorphism in recurrent hepatitis C infection after liver transplantation. Transplantation (2006) 0.84
Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver Int (2007) 0.81
Protocol liver allograft biopsies. Transplantation (2008) 0.80
Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg (2006) 0.80
Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence. Liver Transpl (2011) 0.79
A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. J Viral Hepat (2009) 0.78
Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence. Clin Transplant (2011) 0.78
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology (2009) 3.20
Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes. Transpl Int (2013) 2.62
Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab (2006) 1.68
Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci U S A (2010) 1.66
Endoscopic use of human thrombin in bleeding gastric varices. Am J Gastroenterol (2002) 1.65
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res (2010) 1.58
Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl (2008) 1.56
Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood (2012) 1.54
Transjugular intrahepatic portosystemic stent-shunt and its effects on orthotopic liver transplantation. Eur J Gastroenterol Hepatol (2002) 1.54
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology (2010) 1.44
Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol (2004) 1.41
Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery (2002) 1.29
Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens (2010) 1.22
Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int (2012) 1.19
Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology (2012) 1.16
Live donor liver transplantation in high MELD score recipients. Ann Surg (2010) 1.14
Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers (2007) 1.10
Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl (2012) 1.06
Analysis and outcomes of right lobe hepatectomy in 101 consecutive living donors. Am J Transplant (2005) 1.04
Metabolic effects of D-psicose in rats: studies on faecal and urinary excretion and caecal fermentation. Asia Pac J Clin Nutr (2003) 1.02
Can genetic variations predict HCV treatment outcomes? J Hepatol (2008) 1.01
The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology (2009) 1.01
HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat (2006) 1.01
A graft to body weight ratio less than 0.8 does not exclude adult-to-adult right-lobe living donor liver transplantation. Liver Transpl (2009) 1.00
Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation (2009) 1.00
Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-based screening. Bioconjug Chem (2008) 0.98
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release (2008) 0.98
Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol (2012) 0.97
An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett (2004) 0.96
Glucocorticoid reamplification within cells intensifies NF-kappaB and MAPK signaling and reinforces inflammation in activated preadipocytes. Am J Physiol Endocrinol Metab (2009) 0.95
Increased ischemic injury in old mouse liver: an ATP-dependent mechanism. Liver Transpl (2007) 0.95
Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications. Liver Int (2007) 0.93
Transgenic mice overexpressing human Bcl-2 are resistant to hepatic ischemia and reperfusion. J Hepatol (2002) 0.93
Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol (2010) 0.93
Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol (2002) 0.93
Liver transplantation in the critically ill: a multicenter Canadian retrospective cohort study. Crit Care (2013) 0.93
The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl (2008) 0.92
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin Sci (Lond) (2003) 0.92
CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett (2009) 0.92
Gene and phenotype analysis of congenital generalized lipodystrophy in Japanese: a novel homozygous nonsense mutation in seipin gene. J Clin Endocrinol Metab (2004) 0.92
Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl (2015) 0.91
GPR40 gene expression in human pancreas and insulinoma. Biochem Biophys Res Commun (2005) 0.91
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res (2010) 0.91
Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation (2002) 0.91
Immunosurveillance of alveolar echinococcosis by specific humoral and cellular immune tests: long-term analysis of the Swiss chemotherapy trial (1976-2001). J Hepatol (2004) 0.90
Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma. Transpl Int (2014) 0.90
A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. Biomed Chromatogr (2002) 0.89
Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation. Liver Transpl (2009) 0.89
A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis E in Liver Transplant Recipients in Japan. EBioMedicine (2015) 0.89
Supplements in human islet culture: human serum albumin is inferior to fetal bovine serum. Cell Transplant (2012) 0.89
The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol (2008) 0.88
Role of regulatory T cells in the promotion of transplant tolerance. Liver Transpl (2012) 0.88
Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review. Liver Int (2011) 0.88
Effects of oral acute administration and subchronic feeding of several levels of D-psicose in rats. J Nutr Sci Vitaminol (Tokyo) (2002) 0.88
The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol (2010) 0.88
Augmentation of 11beta-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages--role of 11beta-HSD1 in pro-inflammatory properties in macrophages. FEBS Lett (2006) 0.87
Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation (2003) 0.87
Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis. J Gastrointest Surg (2002) 0.87
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorg Med Chem Lett (2010) 0.87
Periaxin mutation causes early-onset but slow-progressive Charcot-Marie-Tooth disease. J Hum Genet (2004) 0.87
Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology (2008) 0.87
Concise synthesis of anti-HIV-1 active (+)-inophyllum B and (+)-calanolide A by application of (-)-quinine-catalyzed intramolecular oxo-Michael addition. J Org Chem (2004) 0.86
Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. Appl Physiol Nutr Metab (2012) 0.86
The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol (2005) 0.86
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab (2006) 0.85
Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis. Liver Transpl (2013) 0.85
Adipose tissue-specific dysregulation of angiotensinogen by oxidative stress in obesity. Metabolism (2010) 0.85
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells. Cancer Immunol Immunother (2013) 0.85
Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. Int J Exp Pathol (2014) 0.85
A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet (2014) 0.84
Subnormothermic ex vivo liver perfusion reduces endothelial cell and bile duct injury after donation after cardiac death pig liver transplantation. Liver Transpl (2014) 0.84
Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology (2002) 0.84
The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. Rambam Maimonides Med J (2010) 0.83
Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis. J Virol (2014) 0.83
Peptide HIV-1 integrase inhibitors from HIV-1 gene products. J Med Chem (2010) 0.83
Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J (2004) 0.83
Living donor liver transplantation in patients with portal vein thrombosis: a survey and review of technical issues. Transplantation (2002) 0.83
Long-term follow-up of biliary complications after adult right-lobe living donor liver transplantation. Clin Transplant (2015) 0.83
Impact of adjuvant radiation therapy for microscopic residual tumor after resection of extrahepatic bile duct cancer. Am J Clin Oncol (2013) 0.82
Financial, vocational, and interpersonal impact of living liver donation. Liver Transpl (2009) 0.82
Application of the two-layer method on pancreas digestion results in improved islet yield and maintained viability of isolated islets. Transplantation (2007) 0.81
Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. Ann Hepatol (2013) 0.81
The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant (2012) 0.80
Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol (2004) 0.80
Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE. PLoS One (2013) 0.80